Do you recommend maintenance immunotherapy after CR on chemotherapy for patients with metastatic TNBC?

The phase 2, KEYNOTE-158 study done in patients with metastatic solid tumors who progressed on at least 1 line of treatment, showed that 29% of 102 patients with TMB high status had an objective response compared to only 6% of 688 patients who had TMB low status, leading to FDA approval for tumor ag...

Atezolizumab was granted accelerated approval by FDA in March 2019 based on data from the phase 3 IMpassion130 trial which demonstrated a statistically significant benefit to progression-free survival with the exploratory regimen vs placebo/chemotherapy (HR, 0.60; 95% CI, 0.48-0.77; P <.0001). Howev...